TransMedics Group Inc
For the period ended Sep 30, 2024. Filed Oct 29, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 29, 2024
TMDX$93.79+6.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(In thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Revenue: | ||||
| Net product revenue | $65,861 | $47,740 | $198,918 | $124,195 |
| Service revenue | 42,900 | 18,690 | 120,998 | 36,254 |
| Total revenue | 108,761 | 66,430 | 319,916 | 160,449 |
| Cost of revenue: | ||||
| Cost of net product revenue | 13,246 | 11,086 | 41,800 | 26,950 |
| Cost of service revenue | 34,670 | 14,682 | 88,048 | 27,330 |
| Total cost of revenue | 47,916 | 25,768 | 129,848 | 54,280 |
| Gross profit | 60,845 | 40,662 | 190,068 | 106,169 |
| Operating expenses: | ||||
| Research, development and clinical trials | 14,266 | 11,132 | 39,504 | 25,294 |
| Acquired in-process research and development expenses | — | 27,212 | — | 27,212 |
| Selling, general and administrative | 42,656 | 30,653 | 121,712 | 84,993 |
| Total operating expenses | 56,922 | 68,997 | 161,216 | 137,499 |
| Income (loss) from operations | 3,923 | (28,335) | 28,852 | (31,330) |
| Other income (expense): | ||||
| Interest expense | (3,617) | (3,590) | (10,838) | (7,186) |
| Interest income and other income (expense) | 3,939 | 4,996 | 10,777 | 7,982 |
| Total other income (expense), net | 322 | 1,406 | (61) | 796 |
| Income (loss) before income taxes | 4,245 | (26,929) | 28,791 | (30,534) |
| (Provision) benefit for income taxes | (29) | 1,507 | (184) | 1,475 |
| Net income (loss) | $4,216 | $(25,422) | $28,607 | $(29,059) |
| Net income (loss) per share: | ||||
| Basic | $0.13 | $(0.78) | $0.86 | $(0.89) |
| Diluted | $0.12 | $(0.78) | $0.81 | $(0.89) |
| Weighted average common shares outstanding: | ||||
| Basic | 33,441,394 | 32,614,059 | 33,108,253 | 32,474,522 |
| Diluted | 35,683,952 | 32,614,059 | 35,218,756 | 32,474,522 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.